Recombinant Human ARPC1B 293 Cell Lysate

• Cat.No.: ARPC1B-8686HCL

Specification

• Description: Antigen standard for actin related protein 2/3 complex, subunit 1B, 41kDa (ARPC1B) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.

Gene Information

• Gene Name: ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa [ Homo sapiens ]
• Official Symbol: ARPC1B
• Synonyms: ARPC1B; actin related protein 2/3 complex, subunit 1B, 41kDa; actin related protein 2/3 complex, subunit 1B (41 kD); actin-related protein 2/3 complex subunit 1B; actin related protein 2/3 complex; subunit 1A (41 kD); ARC41; ARP2/3 protein complex subunit p41; p40 ARC; p41 ARC; arp2/3 complex 41 kDa subunit; p40-ARC; p41-ARC
• Gene ID: 10095
• mRNA Refseq: NM_005720
• Protein Refseq: NP_005711
• MIM: 604223
• UniProt ID: O15143
• Chromosome Location: 7q
• Pathway: B Cell Receptor Signaling Pathway, organism-specific biosystem; Bacterial invasion of epithelial cells, organism-specific biosystem; Bacterial invasion of epithelial cells, conserved biosystem; CDC42 signaling events, organism-specific biosystem; ErbB1 downstream signaling, organism-specific biosystem; Fc gamma R-mediated phagocytosis, organism-specific biosystem; Fc gamma R-mediated phagocytosis, conserved biosystem
• Function: actin binding; structural constituent of cytoskeleton

Reviews

02/18/2023

Their team of experts is highly knowledgeable, responsive, and dedicated to providing prompt solutions to any challenges I may face.

06/25/2021

By harnessing the power of the ARPC1B protein, I can harness its outstanding quality and tap into its potential to obtain dependable and meaningful findings.

11/01/2018

The ARPC1B protein is undoubtedly a superior choice, boasting extraordinary quality that guarantees it will fulfill all my experimental requirements.

Q&As

What diseases or disorders have been associated with dysregulation of the ARPC1B protein?

Dysregulation of the ARPC1B protein has been implicated in various types of cancer, including breast cancer and colorectal cancer. Additionally, mutations or deletions in the ARPC1B gene have been linked to developmental disorders such as intellectual disability and abnormal brain development.

How does the ARPC1B protein contribute to cancer progression?

The ARPC1B protein is involved in cancer progression by promoting cell motility, invasion, and metastasis. It functions within the Arp2/3 complex to facilitate the formation of actin-based protrusions that allow cancer cells to move and invade surrounding tissues.

Can modulation of the ARPC1B protein be considered as a potential therapeutic approach?

Modulation of the ARPC1B protein or its associated Arp2/3 complex could be a potential therapeutic approach for diseases involving aberrant actin cytoskeleton dynamics or cellular motility. However, further research is necessary to fully understand the functional consequences of ARPC1B dysregulation and to develop targeted therapeutic strategies.

Are there any ARPC1B inhibitors or potential therapeutic targets?

Currently, there are no specific inhibitors targeting the ARPC1B protein available for therapeutic use. However, as the Arp2/3 complex is an essential component of actin cytoskeleton regulation, inhibitors targeting the interaction between the complex and its activators may hold potential as anti-cancer agents.

What role does the ARPC1B protein play in brain development and intellectual disability?

ARPC1B is expressed in the developing brain and is crucial for proper neuronal migration and cortical development. Mutations or deletions in the ARPC1B gene have been associated with intellectual disability and cortical malformations, which are thought to result from disrupted actin dynamics impairing the normal development and function of neural circuits.

Are there any known drugs or therapeutic approaches targeting ARPC1B?

Currently, there are no specific drugs or therapeutic interventions targeting ARPC1B. However, as ARPC1B is involved in actin dynamics and cell migration, targeting other components of the actin cytoskeleton or signaling pathways that regulate actin polymerization may indirectly impact ARPC1B function and could be explored as potential therapeutic strategies.